Department of Internal Medicine, Kitamura Memorial Clinic, Tokyo.
Department of Cardiology, Shin-Oyama City Hospital, Tochigi.
J Hypertens. 2019 Jun;37(6):1301-1307. doi: 10.1097/HJH.0000000000002034.
We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project.
All patients had received aspirin (100 mg/day) or no aspirin. BP subgroups were defined as low (average SBP from the baseline to the year of the events <130 mmHg), moderate (≥130 and <140 mmHg), and high (≥140 mmHg). The mean duration of follow-up was 5.02 years.
In hypertensive patients (n = 12 278) aspirin had no significant impact on the primary outcome of death from cardiovascular disease, nonfatal stroke, and nonfatal myocardial infarction. On the other hand, aspirin increased the incidence of serious extracranial hemorrhage [hazard ratio, 1.81; 95% confidence interval (CI), 1.18-2.77; P = 0.0064] and tended to increase hemorrhagic stroke (hazard ratio, 1.75; CI, 0.99-3.07; P = 0.053). Aspirin had no effect on the primary outcome in any of the BP subgroups, and was associated with increased hemorrhagic stroke in the high BP group (hazard ratio, 3.51; CI, 1.29-9.51; P = 0.014); serious extracranial hemorrhage was elevated or tended to elevate in the moderate (hazard ratio, 2.53; CI, 1.18-5.45; P = 0.017) and high (hazard ratio, 2.14; CI, 1.00-4.56; P = 0.050) BP groups.
In aged Japanese hypertensive patients, these data demonstrated no overall benefit of low-dose aspirin therapy although treatment was associated with an elevated risk of hemorrhagic events.
我们利用日本初级预防项目中年龄在 60-85 岁、患有高血压、血脂异常和/或糖尿病但无心血管疾病的患者的数据,研究低剂量乙酰水杨酸(阿司匹林)对心血管事件一级预防的疗效是否受血压(BP)的影响。
所有患者均接受阿司匹林(100mg/天)或不接受阿司匹林治疗。血压亚组定义为低(从基线到事件发生年度的平均收缩压<130mmHg)、中(≥130 且<140mmHg)和高(≥140mmHg)。中位随访时间为 5.02 年。
在高血压患者(n=12278)中,阿司匹林对心血管疾病死亡、非致死性卒中及非致死性心肌梗死的主要结局无显著影响。另一方面,阿司匹林增加了严重颅外出血的发生率[风险比,1.81;95%置信区间(CI),1.18-2.77;P=0.0064],且倾向于增加出血性卒中(风险比,1.75;CI,0.99-3.07;P=0.053)。阿司匹林在任何血压亚组中对主要结局均无影响,且与高 BP 组的出血性卒中增加相关(风险比,3.51;CI,1.29-9.51;P=0.014);在中(风险比,2.53;CI,1.18-5.45;P=0.017)和高(风险比,2.14;CI,1.00-4.56;P=0.050)BP 组中,严重颅外出血增加或有增加趋势。
在日本老年高血压患者中,尽管低剂量阿司匹林治疗与出血事件风险增加相关,但总体上并未显示出治疗益处。